Nektar Therapeutics Gestione

Gestione criteri di controllo 3/4

Nektar Therapeutics Il CEO è Howard Robin, nominato in Jan2007, e ha un mandato di 17.83 anni. la retribuzione annua totale è $ 3.14M, composta da 34.6% di stipendio e 65.4% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 0.37% delle azioni della società, per un valore di $ 680.51K. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 5.8 anni e 16.3 anni.

Informazioni chiave

Howard Robin

Amministratore delegato

US$3.1m

Compenso totale

Percentuale dello stipendio del CEO	34.6%
Mandato del CEO	17.8yrs
Proprietà del CEO	0.4%
Durata media del management	5.8yrs
Durata media del Consiglio di amministrazione	16.3yrs

Aggiornamenti recenti sulla gestione

Recent updates

Investor Optimism Abounds Nektar Therapeutics (NASDAQ:NKTR) But Growth Is Lacking

Oct 18

Some Nektar Therapeutics (NASDAQ:NKTR) Shareholders Look For Exit As Shares Take 35% Pounding

Jun 19

There's No Escaping Nektar Therapeutics' (NASDAQ:NKTR) Muted Revenues Despite A 44% Share Price Rise

Feb 15

Nektar Therapeutics' (NASDAQ:NKTR) Business And Shares Still Trailing The Industry

Dec 31

Is Nektar Therapeutics (NASDAQ:NKTR) In A Good Position To Deliver On Growth Plans?

Aug 19

Nektar: Time To Abandon Ship

Jul 17

Nektar promotes internal executive to CFO role

Jul 01

We Think Nektar Therapeutics (NASDAQ:NKTR) Needs To Drive Business Growth Carefully

May 11

After A High-Profile Failure In Melanoma, Nektar Therapeutics' Value Shifts To Its Early-Stage Pipeline

Apr 04

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Howard Robin rispetto agli utili di Nektar Therapeutics?
Data	Compenso totale	Stipendio	Guadagni aziendali
Sep 30 2024	n/a	n/a	-US$168m
Jun 30 2024	n/a	n/a	-US$177m
Mar 31 2024	n/a	n/a	-US$176m
Dec 31 2023	US$3m	US$1m	-US$276m
Sep 30 2023	n/a	n/a	-US$294m
Jun 30 2023	n/a	n/a	-US$307m
Mar 31 2023	n/a	n/a	-US$415m
Dec 31 2022	US$11m	US$1m	-US$368m
Sep 30 2022	n/a	n/a	-US$454m
Jun 30 2022	n/a	n/a	-US$525m
Mar 31 2022	n/a	n/a	-US$491m
Dec 31 2021	US$11m	US$1m	-US$524m
Sep 30 2021	n/a	n/a	-US$495m
Jun 30 2021	n/a	n/a	-US$474m
Mar 31 2021	n/a	n/a	-US$429m
Dec 31 2020	US$11m	US$1m	-US$444m
Sep 30 2020	n/a	n/a	-US$439m
Jun 30 2020	n/a	n/a	-US$429m
Mar 31 2020	n/a	n/a	-US$460m
Dec 31 2019	US$10m	US$1m	-US$441m
Sep 30 2019	n/a	n/a	-US$427m
Jun 30 2019	n/a	n/a	-US$424m
Mar 31 2019	n/a	n/a	US$657m
Dec 31 2018	US$13m	US$969k	US$681m
Sep 30 2018	n/a	n/a	US$746m
Jun 30 2018	n/a	n/a	US$903m
Mar 31 2018	n/a	n/a	-US$129m
Dec 31 2017	US$18m	US$941k	-US$97m

Compensazione vs Mercato: La retribuzione totale di Howard ($USD 3.14M ) è superiore alla media delle aziende di dimensioni simili nel mercato US ($USD 1.47M ).

Compensazione vs guadagni: La retribuzione di Howard è stata coerente con le performance aziendali dell'ultimo anno.

AMMINISTRATORE DELEGATO

Howard Robin (71 yo)

17.8yrs

Mandato

US$3,135,576

Compensazione

Mr. Howard W. Robin has been the Chief Executive Officer and the President of Prime Holdings & Investments Inc. since July 2001. Mr. Robin has been the Chief Executive Officer and President of Nektar Thera...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Howard Robin	CEO, President & Director	17.8yrs	US$3.14m	0.37% $ 680.5k
Sandra Gardiner	Chief Financial Officer	1.6yrs	US$376.30k	Nessun dato
Mark Wilson	Senior VP	8.3yrs	US$1.10m	0.12% $ 221.0k
Jonathan Zalevsky	Chief Research & Development Officer	5.1yrs	US$1.77m	0.13% $ 245.5k
Vivian Wu	Director of Investor Relations & Corporate Affairs	no data	Nessun dato	Nessun dato
Robert Bacci	Senior Vice President of Human Resources & Facilities Operations	2.9yrs	Nessun dato	Nessun dato
Jennifer Ruddock	Chief Business Officer	5.8yrs	Nessun dato	Nessun dato
Mary Tagliaferri	Chief Medical Officer	7yrs	Nessun dato	Nessun dato

5.8yrs

Durata media

58yo

Età media

Gestione esperta: Il team dirigenziale di NKTR è esperto e expertise (durata media dell'incarico 5.8 anni).

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Howard Robin	CEO, President & Director	17.8yrs	US$3.14m	0.37% $ 680.5k
Robert Chess	Independent Chairman of the Board	32.5yrs	US$176.22k	0.14% $ 264.2k
R. Greer	Independent Director	14.8yrs	US$170.22k	0.16% $ 306.6k
Roy Whitfield	Lead Independent Director	24.3yrs	US$170.22k	0.16% $ 290.6k
Jeffrey Ajer	Independent Director	7.2yrs	US$134.22k	0.019% $ 34.5k
Diana Brainard	Independent Director	3yrs	US$112.72k	0.012% $ 22.7k

16.3yrs

Durata media

66.5yo

Età media

Consiglio di amministrazione esperto: Il consiglio di amministrazione di NKTR è composto da personale esperto e esperto (durata media dell'incarico 16.3 anni).

Nektar Therapeutics Gestione

Gestione criteri di controllo 3/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Nektar Therapeutics, Annual General Meeting, Jun 05, 2024

CEO, President & Director recently sold US$59k worth of stock

Insufficient new directors

CEO, President & Director recently sold US$136k worth of stock

Insider recently sold US$48k worth of stock

Independent Director notifies of intention to sell stock

Recent updates

Consensus revenue estimates increase by 22%

Nektar Therapeutics Provides Earnings Guidance for the Full Year of 2024

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

Nektar and Collaborators Present Late-breaking Results from Phase 2 Study of NKTR-255 for the Treatment of Radiation Induced Lymphopenia in Locally Advanced Non-Small Cell Lung Cancer Patients at Society for Immunotherapy of Cancer (SITC) Annual Meeting

Ampersand Management LLC entered into an Asset Purchase Agreement to acquire Manufacturing Facility and Reagent Supply Business in Huntsville, Alabama of Nektar Therapeutics from Nektar Therapeutics (NasdaqCM:NKTR) for $90 million.

Ampersand Management LLC entered into an Asset Purchase Agreement to acquire Manufacturing Facility and Reagent Supply Business in Huntsville, Alabama of Nektar Therapeutics from Nektar Therapeutics (NasdaqCM:NKTR) for $90 million.

New major risk - Revenue and earnings growth

Nektar Therapeutics to Report Q3, 2024 Results on Nov 07, 2024

Nektar Therapeutics Announces Publication in Nature Communications of Results from Phase 1B Studies of Rezpegaldesleukin in Two Inflammatory Skin Diseases

Investor Optimism Abounds Nektar Therapeutics (NASDAQ:NKTR) But Growth Is Lacking

Nektar Therapeutics Announces Publication in Blood of Phase 1 Data for Novel II-15 Agonist NKTR-255 in Combination with Autologous CD19-22 Car-T Cell Therapy in Patients with B-Cell Acute Lymphoblastic Leukemia

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Nektar Therapeutics to Report Q2, 2024 Results on Aug 08, 2024

Some Nektar Therapeutics (NASDAQ:NKTR) Shareholders Look For Exit As Shares Take 35% Pounding

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Nektar Therapeutics to Report Q1, 2024 Results on May 09, 2024

Nektar Therapeutics, Annual General Meeting, Jun 05, 2024

New major risk - Share price stability

Nektar Therapeutics announced that it has received $30 million in funding from TCG Crossover Management, LLC

Consensus EPS estimates fall by 12%

Full year 2023 earnings: EPS in line with analyst expectations despite revenue beat

Nektar Therapeutics Announces Initiation of Phase 2B Clinical Study Evaluating Rezpegaldesleukin in Patients with Severe to Very Severe Alopecia Areata

Nektar Therapeutics announced that it expects to receive $30 million in funding from TCG Crossover Management, LLC

Nektar Therapeutics to Report Q4, 2023 Results on Mar 04, 2024

There's No Escaping Nektar Therapeutics' (NASDAQ:NKTR) Muted Revenues Despite A 44% Share Price Rise

Price target decreased by 83% to US$0.50

Nektar Therapeutics' (NASDAQ:NKTR) Business And Shares Still Trailing The Industry

Nasdaq States Nektar Therapeutics Eligible for an Additional 180 Calendar Day Period, or Until May 20, 2024, to Regain Compliance with the Minimum Bid Price Requirement

Nasdaq States Nektar Therapeutics Eligible for an Additional 180 Calendar Day Period, or Until May 20, 2024, to Regain Compliance with the Minimum Bid Price Requirement

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Is Nektar Therapeutics (NASDAQ:NKTR) In A Good Position To Invest In Growth?

Nektar Therapeutics to Report Q3, 2023 Results on Nov 07, 2023

Nektar Therapeutics Presents New Responder Data for Rezpegaldesleukin, A First-In-Class Selective Regulatory T-Cell Therapy

Nektar Therapeutics Announces New Clinical Study Collaboration with Cellular Biomedicine Group Inc. to Evaluate Nktr-255 in Combination with C-Til051 in Advanced Non-Small Cell Lung Cancer

Price target increased by 21% to US$2.88

Nektar Therapeutics Announces Promising New Data from Phase 1b Study of Rezpegaldesleukin in Moderate-To-Severe Atopic Dermatitis

Price target increased by 14% to US$2.70

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

New major risk - Share price stability

Nektar Therapeutics Announces Promising New and Corrected Rezpegaldesleukin Efficacy Data Which Were Previously Reported in 2022 and Incorrectly Calculated by Former Collaborator Eli Lilly & Company

Nektar Therapeutics to Report Q2, 2023 Results on Aug 08, 2023

Price target decreased by 7.3% to US$2.35

New minor risk - Market cap size

Nektar Therapeutics(NasdaqGS:NKTR) dropped from Russell 2000 Index

New minor risk - Market cap size

Nektar Therapeutics Receives Notice from The Nasdaq Global Select Market Due to Non-Compliance with the Minimum Bid Price Rule

Price target increased by 18% to US$3.00

Consensus EPS estimates fall by 63%, revenue upgraded

Price target decreased by 7.8% to US$2.70

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Nektar Therapeutics Reports Impairment of Goodwill for the First Quarter Ended March 31, 2023

Is Nektar Therapeutics (NASDAQ:NKTR) In A Good Position To Invest In Growth?

Full year 2022 earnings: EPS exceeds analyst expectations

Price target decreased by 21% to US$3.60

CEO, President & Director recently sold US$59k worth of stock

Here's Why Nektar Therapeutics (NASDAQ:NKTR) Must Use Its Cash Wisely

Insufficient new directors

CEO, President & Director recently sold US$136k worth of stock

Insider recently sold US$48k worth of stock

Nektar and Collaborators Announce Publication in Blood Advances of Preclinical Data Demonstrating NKTR-255, A Novel Polymer-Conjugated Human IL-15, Improves Efficacy of CD19-Targeted CAR-T Cell Immunotherapy

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Nektar Therapeutics to Report Q3, 2022 Results on Nov 03, 2022

Nektar Therapeutics (NasdaqGS:NKTR) submitted a non-binding proposal to acquire PureTech Health plc (LSE:PRTC).

Independent Director notifies of intention to sell stock

Nektar Therapeutics Presents Data for Rezpegaldesleukin (LY3471851) in Patients with Atopic Dermatitis and Psoriasis from Two Separate Clinical Studies at 2022 European Academy of Dermatology (Eadv) Congress

Insider notifies of intention to sell stock

CEO, President & Director recently sold US$65k worth of stock

Is Nektar Therapeutics (NASDAQ:NKTR) In A Good Position To Deliver On Growth Plans?

Nektar Therapeutics Announces Preclinical Publication of Data for NKTR-255 and Its Observed Improvement of NK Cell Function in Multiple Myeloma